Mark J Levis

Summary

Publications

  1. pmc Will newer tyrosine kinase inhibitors have an impact in AML?
    Mark J Levis
    Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Best Pract Res Clin Haematol 23:489-94. 2010

Detail Information

Publications1

  1. pmc Will newer tyrosine kinase inhibitors have an impact in AML?
    Mark J Levis
    Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Best Pract Res Clin Haematol 23:489-94. 2010
    ..The newer FLT3 inhibitors appear to be more potent in vivo and have shown more promise than the older agents in monotherapy trials...